Registration - In-house Corporation

GlaxoSmithKline Inc. / Sridhar Venkatesh, General Manager and President

Registration Information

In-house Corporation name: GlaxoSmithKline Inc.
Previous in-house corporation names
Responsible Officer Name: Sridhar Venkatesh, General Manager and President
Responsible Officer Change History
Initial registration start date: 1996-03-25
Registration status: Active
Registration Number: 953603-5088

Associated Communications

Total Number of Communication Reports: 289

Monthly communication reports in the last 6 months: 18

Version 20 of 68 (2011-10-18 to 2011-12-08)

Registration versions:

Version 20 of 68 (2011-10-18 to 2011-12-08)

Lobbying Information

Subject Matters

Constitutional Issues
Consumer Issues
Economic Development
Employment and Training
Financial Institutions
Government Procurement
Health
Industry
Intellectual Property
Internal Trade
International Development
International Relations
International Trade
Labour
Regional Development
Science and Technology
Taxation and Finance

Subject matters added through a monthly communication report

Research and Development

Subject Matter Details

Legislative Proposal, Bill or Resolution

Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.

Policies or Program

Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
National Immunization Strategy. Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients.

Regulation

Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Aboriginal Affairs and Northern Development Canada
Atlantic Canada Opportunities Agency (ACOA)
Canadian International Development Agency (CIDA)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Environment Canada
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Industry Canada
Members of the House of Commons
National Research Council (NRC)
Natural Sciences and Engineering Research Council (NSERC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Public Works and Government Services Canada
Revenue Canada (RC)
Technology Partnerships Canada (TPC)
Treasury Board Of Canada Secretariat (TBS)

Government institutions added through a monthly communication report

Human Resources and Skills Development Canada (HRSDC)
Senate of Canada

In-house Corporation Details

Description of activities

GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.

Responsible officer name and position during the period of this registration

Paul Lucas, President and Chief Executive Officer

Government funding

End date of the last completed financial year: 2010-12-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Ontario Innovation Biopharmaceutical Investment Program (BiP) program	$0.00	Yes

In-house Corporation Contact Information

Address:
7333 Mississauga Road
Mississauga, ON L5N 6L4
Canada

Telephone number: 905-819-3000
Fax number: 905-819-3099

Parent Company Information

GlaxoSmithKline plc
- 980 Great West Road
  Brentford, Middlesex TW89GS
  United Kingdom

Subsidiary Beneficiary Information

GlaxoSmithKline Biologicals / GlaxoSmithKline Biologiques
- 525 Cartier Blvd. W.
  Laval, QC H7V 3S8
  Canada

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Edward Dybka, Vice-President, Marketing | No public offices held
Rav Kumar, Vice President Regulatory Affairs and Pharma Development | No public offices held
Paul Lucas, President and Chief Executive Officer | No public offices held
Patrick McGrade, Vice President, Legal | No public offices held
Grant Perry, Vice President, Public Affairs | No public offices held
John Picken, Vice President, North American Industrial Operations | No public offices held
Herman Van Barneveld, Vice President and Chief Financial Officer | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Craig Stewart, Manager, Federal Affairs | Public offices held

GlaxoSmithKline Inc./

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
GlaxoSmithKline Inc./	2024-04-01	current
GlaxoSmithKline Inc./	2008-07-09	2024-04-01

The following names have been used before July 2, 2008

GlaxoSmithKline
GLAXOSMITHKLINE

GlaxoSmithKline Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Sridhar Venkatesh	2022-12-01	Current
Zach Gana	2022-07-18	2022-12-01
Faris El-Refaie	2020-09-01	2022-07-18
Yoo-Seok Hong	2018-03-01	2020-09-01
Josee Gravelle	2018-02-01	2018-03-01
Paul Lirette	2012-06-15	2018-02-01
Paul Lucas	1996-03-25	2012-06-15

Sridhar Venkatesh, General Manager and President (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15^th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-289 of 289

GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
- Erin Henry, Director General | Centre for Immunization Programs and Surveillance | Public Health Agency of Canada (PHAC)
- Jacqueline Kosche , Director | Vaccine Logistics and Operations | Public Health Agency of Canada (PHAC)
- Christina Jensen, Manager, Canadian Immunization Guide | National Advisory Committee on Immunization Secretariat | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-08-19
Posted date: 2024-09-16
Communication number: 5088-613501 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Eshan Naik, Director of Policy | Minister's office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-08-14
Posted date: 2024-09-16
Communication number: 5088-612849 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Fatima Asghar, Policy Advisor | Health Canada (HC)
- Ella Alvarado De Catleugh , Intern | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-07-22
Posted date: 2024-08-15
Communication number: 5088-611604 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ophelia John, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-07-11
Posted date: 2024-08-15
Communication number: 5088-610284 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Judith Seidman, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2024-06-26
Posted date: 2024-07-15
Communication number: 5088-609321 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Cid Cabillan, Policy Advisor | Immigration, Refugees and Citizenship Canada (IRCC)
Subject Matter of the communication: Health
Communication date: 2024-06-25
Posted date: 2024-07-15
Communication number: 5088-609276 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mohamed-Iqbal Ravalia, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2024-06-19
Posted date: 2024-07-15
Communication number: 5088-609065 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Kmiec, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2024-06-13
Posted date: 2024-07-15
Communication number: 5088-607371 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
- Caroline Menard, Manager | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development, Health
Communication date: 2024-06-04
Posted date: 2024-07-15
Communication number: 5088-606104 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joanna Lam, Policy Advisor | Minister's Office | Indigenous Services Canada (ISC)
Subject Matter of the communication: Health
Communication date: 2024-05-30
Posted date: 2024-06-15
Communication number: 5088-605533 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Erin Henry, Director General | Public Health Agency of Canada (PHAC)
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
- Heather Deehan, Executive Director, Vaccine Distribution and Logistics | Public Health Agency of Canada (PHAC)
- Kelsey Young, Deputy Executive Secretary | NACI | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-05-17
Posted date: 2024-06-15
Communication number: 5088-605174 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development, Health
Communication date: 2024-04-30
Posted date: 2024-05-15
Communication number: 5088-601821 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Semhar Zerat, Director | Programs and Partnerships Division | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-601822 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jaxson Khan, Sr Policy Advisor | MINISTER OF INNOVATION, SCIENCE AND INDUSTRY | Innovation, Science and Economic Development Canada (ISED)
- Laurel Chester, Senior Advisor | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Government Procurement
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-600955 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Colin Deacon, Senator | Senate of Canada
Subject Matter of the communication: Economic Development
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-600954 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Francis Bilodeau, Associate Deputy Minister | Office of the Associate Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Andrea Johnston, Assistant deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Etienne-Rene Massie, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2024-04-15
Posted date: 2024-05-15
Communication number: 5088-600953 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mark Schaan, Senior Assistant Deputy Minister | Strategy and Innovation Policy Sector - Assistant Deputy Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2024-04-15
Posted date: 2024-05-15
Communication number: 5088-600952 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-04-04
Posted date: 2024-05-15
Communication number: 5088-599236 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Anita Anand, President of the Treasury Board | President's Office | Treasury Board Of Canada Secretariat (TBS)
Subject Matter of the communication: Health, Budget
Communication date: 2024-03-15
Posted date: 2024-04-15
Communication number: 5088-597887 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Qasir Hanif, Director of Stakeholder Relations | Minister's Office | Global Affairs Canada (GAC)
- Aram Shoujounian, Policy Advisor | Minister's Office | Global Affairs Canada (GAC)
- Matthew Trnkus, Senior Advisor | Minister's Office | Global Affairs Canada (GAC)
Subject Matter of the communication: Health
Communication date: 2024-02-13
Posted date: 2024-03-15
Communication number: 5088-594057 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ophelia John, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
- Eshan Naik, Director of Policy | Minister's office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-02-13
Posted date: 2024-03-15
Communication number: 5088-592784 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Moen, Chief of Staff | Employment and Social Development Canada (ESDC)
- Lhori Webster, Director of Policy | Employment and Social Development Canada (ESDC)
Subject Matter of the communication: Health
Communication date: 2024-01-26
Posted date: 2024-02-15
Communication number: 5088-591256 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2024-01-22
Posted date: 2024-02-15
Communication number: 5088-591666 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Victor Kandasamy, Policy Advisor | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Government Procurement
Communication date: 2024-01-16
Posted date: 2024-02-15
Communication number: 5088-590987 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ophelia John, Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Government Procurement
Communication date: 2024-01-09
Posted date: 2024-02-15
Communication number: 5088-589793 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Laurel Chester, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-12-14
Posted date: 2024-01-15
Communication number: 5088-587704 (amended from 5088-587698) View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-12-13
Posted date: 2024-01-15
Communication number: 5088-587696 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Sebastien Bock, Deputy Chief of Staff and Director of Policy | Office of the Minister of Health | Health Canada (HC)
- Eshan Naik, Director of Policy | Office of the Leader of the Government in the House of Commons | House of Commons
Subject Matter of the communication: Health
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587771 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Suzy McDonald, Associate Deputy Minister | Finance Canada (FIN)
Subject Matter of the communication: Health, Budget, Economic Development
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587692 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Cindy Evans, Vice President | Emergency Management Branch | Public Health Agency of Canada (PHAC)
- Heather Jeffrey, President | Public Health Agency of Canada (PHAC)
- Joel Denis, Director General | Public Health Agency of Canada (PHAC)
- Erin Schock, Director, Medical Countermeasures Program | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Government Procurement
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587688 (amended from 5088-587654) View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587686 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Stephen Lucas, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587646 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jennifer Miller, Assistant Secretary to the Cabinet | Privy Council Office (PCO)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-12-12
Posted date: 2024-01-15
Communication number: 5088-587630 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel MacDonald, Director General, Drugs for Rare Diseases | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-12-04
Posted date: 2024-01-15
Communication number: 5088-585709 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mary-Rose Brown, Director of Policy | Public Services and Procurement Canada (PSPC)
- Victor Kandasamy, Policy Advisor | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Government Procurement
Communication date: 2023-11-28
Posted date: 2023-12-15
Communication number: 5088-585120 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joel Denis, Director General | Centre for Vaccine and Therapeutic Readiness | Public Health Agency of Canada (PHAC)
- Milan Patel, Director, Vaccine Supply & Assurance | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Government Procurement
Communication date: 2023-11-22
Posted date: 2023-12-15
Communication number: 5088-585026 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mohamed-Iqbal Ravalia, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2023-11-08
Posted date: 2023-12-15
Communication number: 5088-581815 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Francesco Sorbara, Member of Parliment | House of Commons
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-11-06
Posted date: 2023-12-15
Communication number: 5088-581303 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-11-01
Posted date: 2023-12-15
Communication number: 5088-580864 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-10-25
Posted date: 2023-11-15
Communication number: 5088-580355 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ophelia John, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-10-25
Posted date: 2023-11-15
Communication number: 5088-580354 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Brendan Hanley, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2023-10-20
Posted date: 2023-11-15
Communication number: 5088-580150 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ekateryna Nova, Policy Advisor, Seniors | Minister's Office | Employment and Social Development Canada (ESDC)
Subject Matter of the communication: Health
Communication date: 2023-10-17
Posted date: 2023-11-15
Communication number: 5088-579924 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-09-29
Posted date: 2023-10-16
Communication number: 5088-577394 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson, Director General | Biomanufacturing Strategy Implementation Team | Innovation, Science and Economic Development Canada (ISED)
- Kasondra White, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
- Joel Denis, Director General | Vaccine Supply and Assurance | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-09-20
Posted date: 2023-10-16
Communication number: 5088-577107 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marie-France Proulx, Director of Communications | Minister's Office | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-09-19
Posted date: 2023-10-16
Communication number: 5088-577036 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-09-13
Posted date: 2023-10-16
Communication number: 5088-576325 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jed Graham, Policy Advisor | Health Canada (HC)
- Eshan Naik, Director of Policy | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-09-11
Posted date: 2023-10-16
Communication number: 5088-575822 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-08-25
Posted date: 2023-09-15
Communication number: 5088-575302 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Eric Bourbonnais, Director, Investment Opportunities | Strategic Innovation Fund | Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
- Celine Menard, Director General | Financial Analysis and Oversight Branch | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-08-24
Posted date: 2023-09-15
Communication number: 5088-575301 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-07-31
Posted date: 2023-08-15
Communication number: 5088-573671 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Yves Duclos, Minister of Health | Health Canada (HC)
- Jamie Kippen, Chief of Staff | Health Canada (HC)
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Economic Development, Government Procurement
Communication date: 2023-07-13
Posted date: 2023-08-15
Communication number: 5088-573210 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-06-26
Posted date: 2023-07-15
Communication number: 5088-570732 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ritu Banerjee, Assistant Deputy Minister | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson, Director General | Biomanufacturing Strategy Implementation Team | Innovation, Science and Economic Development Canada (ISED)
- Andy Fillmore, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-06-06
Posted date: 2023-07-15
Communication number: 5088-569574 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Yash Nanda, Policy Advisor | Minister's Office | Finance Canada (FIN)
Subject Matter of the communication: Health
Communication date: 2023-05-10
Posted date: 2023-05-10
Communication number: 5088-564623 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-05-01
Posted date: 2023-06-15
Communication number: 5088-563898 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bianca Hossain, Senior Special Assistant | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2023-04-27
Posted date: 2023-05-15
Communication number: 5088-563613 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
- Jed Graham, Policy advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-04-27
Posted date: 2023-05-15
Communication number: 5088-563611 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Morgan, Director General | Policy, Planning and International | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-04-25
Posted date: 2023-04-26
Communication number: 5088-563527 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jo Voisin, Assistant Deputy Minister | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-04-25
Posted date: 2023-04-26
Communication number: 5088-563526 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-03-31
Posted date: 2023-04-03
Communication number: 5088-560918 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Patrick Vaughan, Special Assistant Communications and Stakeholder Relations Manager | Office of the Minister of Seniors | Employment and Social Development Canada (ESDC)
Subject Matter of the communication: Health
Communication date: 2023-03-16
Posted date: 2023-04-15
Communication number: 5088-560277 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bianca Hossain, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-02-09
Posted date: 2023-03-15
Communication number: 5088-555431 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Yash Nanda, Policy Advisor | Finance Canada (FIN)
Subject Matter of the communication: Health, Budget
Communication date: 2023-01-31
Posted date: 2023-02-15
Communication number: 5088-554923 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-01-30
Posted date: 2023-02-15
Communication number: 5088-554882 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Pierre Mizero, Manager, Integration, Outreach & Partnerships | Strategic Innovation Fund | Innovation, Science and Economic Development Canada (ISED)
- Alison McConnell, Deputy Director, Innovation Projects Directorate | Strategic Innovation Fund | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-01-26
Posted date: 2023-02-15
Communication number: 5088-554834 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Eric Dagenais, Senior Assistant Deputy Minister | Assistant Deputy Minister's Office | Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas, Deputy Minister | Health Canada (HC)
- Nancy Hamzawi, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2023-01-26
Posted date: 2023-02-15
Communication number: 5088-554812 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-01-24
Posted date: 2023-02-15
Communication number: 5088-554724 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Government Procurement
Communication date: 2023-01-16
Posted date: 2023-02-15
Communication number: 5088-554243 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development, Research and Development
Communication date: 2023-01-03
Posted date: 2023-02-15
Communication number: 5088-552822 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bianca Hossain, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2022-12-16
Posted date: 2023-01-16
Communication number: 5088-552368 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health, Government Procurement
Communication date: 2022-12-01
Posted date: 2023-01-16
Communication number: 5088-548814 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Zachary Nixon, Senior Advisor | Economic Development and Official Languages
- Camille Benoit-Blouin, Special Assistant | Economic Development and Official Languages
Subject Matter of the communication: Health, Economic Development
Communication date: 2022-11-23
Posted date: 2022-12-15
Communication number: 5088-548460 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ashley Wright, Chief of Staff to the Minister | Pacific Economic Development Canada (PacifiCan)
- Jessica La Forge, Policy Advisor | Pacific Economic Development Canada (PacifiCan)
- Neor Tiku, Student | Pacific Economic Development Canada (PacifiCan)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2022-11-23
Posted date: 2022-12-15
Communication number: 5088-548459 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jessie Pierre, Director of Policy | Economic Development and Official Languages
- Chelsea Kusnick, Director of Communications | Economic Development and Official Languages
Subject Matter of the communication: Health, Economic Development
Communication date: 2022-11-23
Posted date: 2022-12-15
Communication number: 5088-548458 (amended from 5088-548457) View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Alexandre Boulé, Directeur aux Affaires regionales pour le Lieutenant du Quebec | Canadian Heritage (PCH)
- Jamee St-Hilaire, Regional Affairs Manager | Canadian Heritage (PCH)
Subject Matter of the communication: Health, Economic Development
Communication date: 2022-11-23
Posted date: 2022-12-15
Communication number: 5088-548453 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Susan Fitzpatrick, Head of the Canada Drug Agency Transition Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-10-27
Posted date: 2022-10-28
Communication number: 5088-544823 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Brendan Hanley, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2022-10-24
Posted date: 2022-10-25
Communication number: 5088-544692 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2022-09-20
Posted date: 2022-09-20
Communication number: 5088-542166 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jed Graham, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-09-08
Posted date: 2022-09-08
Communication number: 5088-540894 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Yves Duclos, Minister of Health | Health Canada (HC)
- Marjolaine Provost, Director of Communications | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-07-15
Posted date: 2022-08-12
Communication number: 5088-539625 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- François-Olivier Picard, Policy advisor | Office of the Minister of Health | Health Canada (HC)
- Marjolaine Provost, Director of Communications | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-07-07
Posted date: 2022-08-12
Communication number: 5088-539627 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau , Executive Director | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-06-17
Posted date: 2022-06-30
Communication number: 5088-536504 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director | Office of Pharmaceutical Management Strategies | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-06-17
Posted date: 2022-06-27
Communication number: 5088-536301 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Yash Nanda, Policy Advisor | Finance Canada (FIN)
Subject Matter of the communication: Health
Communication date: 2022-06-16
Posted date: 2022-06-16
Communication number: 5088-535930 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Douglas Clark , Executive Director | Patented Medicine Prices Review Board (PMPRB)
Subject Matter of the communication: Health
Communication date: 2022-06-01
Posted date: 2022-06-30
Communication number: 5088-536505 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- François-Olivier Picard, Policy advisor | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-05-17
Posted date: 2022-05-17
Communication number: 5088-532498 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-05-06
Posted date: 2022-05-17
Communication number: 5088-530974 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Majid Jowhari, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2022-04-12
Posted date: 2022-05-17
Communication number: 5088-532499 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mary-Rose Brown, Senior Policy Advisor | Minister's Office | Finance Canada (FIN)
Subject Matter of the communication: Health
Communication date: 2022-02-16
Posted date: 2022-03-15
Communication number: 5088-523565 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marcus Powlowski, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2021-07-29
Posted date: 2021-08-16
Communication number: 5088-511962 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marcus Powlowski, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2021-05-27
Posted date: 2021-06-15
Communication number: 5088-506415 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Celine Caira, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2021-04-29
Posted date: 2021-05-19
Communication number: 5088-506150 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marcus Powlowski, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2021-04-29
Posted date: 2021-05-19
Communication number: 5088-506149 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kathryn Nowers, Director of Policy | Health Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2020-12-11
Posted date: 2021-01-11
Communication number: 5088-492555 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Rempel, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2020-12-04
Posted date: 2021-01-13
Communication number: 5088-492948 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Rempel, Opposition Health Critic | Conservative Party of Canada | House of Commons
Subject Matter of the communication: Health
Communication date: 2020-12-03
Posted date: 2021-01-15
Communication number: 5088-489149 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Helen Gao, Policy Advisor | Office of the Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2020-11-19
Posted date: 2020-12-04
Communication number: 5088-489148 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Stephanie Muccilli, Director of Policy | Office of the Minister for Seniors | Employment and Social Development Canada (ESDC)
Subject Matter of the communication: Health
Communication date: 2020-10-07
Posted date: 2020-11-16
Communication number: 5088-485450 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marcus Powlowski, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2020-10-01
Posted date: 2020-10-19
Communication number: 5088-485449 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Seth Pickard, Director of Parliamentary Affairs | Office of the Minister of Justice | Justice Canada (JC)
- Nicola Langille, Director | Office of the Minister of Justice | Justice Canada (JC)
Subject Matter of the communication: Intellectual Property
Communication date: 2020-07-02
Posted date: 2020-07-02
Communication number: 5088-476507 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Amanda Woodley, Assistant to the Parliamentary Secretary | Offuce of the Minister | Innovation, Science and Economic Development Canada (ISED)
- Michael Power, Director of Parliamentary Affairs | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2020-06-17
Posted date: 2020-06-25
Communication number: 5088-476334 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sabina Saini, Chief of Staff | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2020-01-10
Posted date: 2020-01-31
Communication number: 5088-463171 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gagan Sikand, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Science and Technology
Communication date: 2019-12-18
Posted date: 2019-12-23
Communication number: 5088-462093 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Carolyn Bennett, Minister of Indeginous and Northern Affairs | House of Commons
Subject Matter of the communication: Health
Communication date: 2019-08-13
Posted date: 2019-09-16
Communication number: 5088-459789 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Amanda Woodley, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Government Procurement, Economic Development
Communication date: 2019-06-26
Posted date: 2019-07-03
Communication number: 5088-456642 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Travis Gordon, Policy Advisor | Health Canada, Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2019-05-16
Posted date: 2019-05-21
Communication number: 5088-453188 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bill Casey, Member of Parliament for Cumberland—Colchester | House of Commons
Subject Matter of the communication: Health
Communication date: 2019-05-16
Posted date: 2019-05-21
Communication number: 5088-453187 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Senator Ravalia, Senator, Newfoundland and Labrador | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2019-05-15
Posted date: 2019-05-21
Communication number: 5088-453189 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dylan Marando, Policy Director | ESDC Minister’s Office | Employment and Social Development Canada (ESDC)
Subject Matter of the communication: Health
Communication date: 2019-04-01
Posted date: 2019-04-01
Communication number: 5088-448741 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel Lauzon, Chief of Staff | Minister Joly's Office (ISED) | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health
Communication date: 2019-03-29
Posted date: 2019-05-21
Communication number: 5088-453186 (amended from 5088-448742) View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gagan Sikand, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Economic Development
Communication date: 2019-01-30
Posted date: 2019-02-11
Communication number: 5088-444770 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dev Saxena, Senior Policy Advisor | Finance Canada (FIN)
Subject Matter of the communication: Health, Science and Technology
Communication date: 2018-11-09
Posted date: 2018-11-26
Communication number: 5088-440238 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Navdeep Bains, Minister of Innovation, Science, and Economic Development | Innovation, Science and Economic Development Canada (ISED)
- Gianluca Cairo, Chief of Staff | Prime Minister's Office (PMO)
- David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
- Hilary Travis, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Economic Development
Communication date: 2018-09-19
Posted date: 2018-10-01
Communication number: 5088-434280 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
- Mathieu Bouchard, Senior Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Science and Technology, Economic Development
Communication date: 2018-07-12
Posted date: 2018-07-23
Communication number: 5088-431512 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Doug Clark, Executive Director | PMPRB | Patented Medicine Prices Review Board (PMPRB)
Subject Matter of the communication: Health, Science and Technology, Economic Development, Research and Development
Communication date: 2018-06-28
Posted date: 2018-07-05
Communication number: 5088-430073 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
- Nancy Faraday-Smith, Manager | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Science and Technology, Research and Development
Communication date: 2018-06-06
Posted date: 2018-06-15
Communication number: 5088-427857 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sheryl Groenweg, Director General | Manufacturing and Life Sciences | Innovation, Science and Economic Development Canada (ISED)
- Nancy Faraday-Smith, Manager | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
- Colin Reynolds, Sector Analysis Officer | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Science and Technology, Economic Development, Research and Development
Communication date: 2018-05-14
Posted date: 2018-05-22
Communication number: 5088-427115 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sarah Hussaini, Special Assistant | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Economic Development
Communication date: 2018-04-30
Posted date: 2018-05-01
Communication number: 5088-424898 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gianluca Cairo, Chief of Staff | Minister of Innovation, Science, and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development
Communication date: 2018-03-08
Posted date: 2018-04-09
Communication number: 5088-423287 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Travis Gordon, Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2018-03-08
Posted date: 2018-04-09
Communication number: 5088-423286 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kimberly Elmslie, Assistant Deputy Minister | Infectious Disease Prevention and Control Branch | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2018-03-08
Posted date: 2018-04-09
Communication number: 5088-423280 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
- Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Economic Development
Communication date: 2018-01-30
Posted date: 2018-02-15
Communication number: 5088-418755 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Robert Oliphant, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Taxation and Finance, Economic Development, Research and Development
Communication date: 2017-11-15
Posted date: 2017-11-20
Communication number: 5088-413997 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
- Hilary Travis, Special Assistant - Policy | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Taxation and Finance, Economic Development, Research and Development
Communication date: 2017-11-14
Posted date: 2017-11-20
Communication number: 5088-413996 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gagan Sikand, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Taxation and Finance, Economic Development, Research and Development
Communication date: 2017-11-09
Posted date: 2017-11-20
Communication number: 5088-413994 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Caroline Pitfield, Director of Policy | Health Canada (HC)
- Monique Lugli, Senior Advisor | Health Canada (HC)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2017-11-06
Posted date: 2017-11-20
Communication number: 5088-413992 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kathryn Nowers, Policy Advisor | Health Canada (HC)
Subject Matter of the communication: Health, Intellectual Property, Science and Technology, Economic Development, Research and Development
Communication date: 2017-10-30
Posted date: 2017-10-31
Communication number: 5088-410991 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Intellectual Property, Economic Development, Research and Development
Communication date: 2017-10-30
Posted date: 2017-10-31
Communication number: 5088-410990 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tyler Meredith, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Intellectual Property, Economic Development, Research and Development
Communication date: 2017-10-02
Posted date: 2017-10-31
Communication number: 5088-410989 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Hilary Travis, Special Assistant (Policy) | Innovation, Science and Economic Development Canada (ISED)
- Parvinder Sachdeva, Policy Advisor | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Intellectual Property, International Trade, Economic Development, Research and Development
Communication date: 2017-10-02
Posted date: 2017-10-31
Communication number: 5088-410986 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
Subject Matter of the communication: Consumer Issues, Health, Intellectual Property, Research and Development
Communication date: 2016-07-14
Posted date: 2016-08-15
Communication number: 5088-382428 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Navdeep Bains, Minister of Innovation, Science and Economic Development Canada | Innovation, Science and Economic Development Canada (ISED)
- John Knubley, Deputy Minister of Innovation, Science and Economic Development Canada | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Intellectual Property, Internal Trade, Science and Technology, Economic Development, Research and Development
Communication date: 2016-06-06
Posted date: 2016-07-15
Communication number: 5088-381398 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Intellectual Property
Communication date: 2016-04-14
Posted date: 2016-06-08
Communication number: 5088-378423 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Greg Taylor, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
- Krista Outhwaite, Associate Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Government Procurement, Health
Communication date: 2014-12-17
Posted date: 2015-01-15
Communication number: 5088-344009 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Barbara Glover, Assistant Deputy Minister | Departmental Oversight Branch | Public Works and Government Services Canada
Subject Matter of the communication: Government Procurement
Communication date: 2014-12-09
Posted date: 2015-01-15
Communication number: 5088-344007 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Lynette Corbett, Chief of Staff | Minister's Office | Public Works and Government Services Canada
- Ryan Greer, Senior Policy Advisor | Minister's Office | Public Works and Government Services Canada
- Tim Oracheski, Director, Policy | Minister's Office | Public Works and Government Services Canada
Subject Matter of the communication: Government Procurement
Communication date: 2014-10-31
Posted date: 2014-11-17
Communication number: 5088-339048 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Claire Caloren, Associate ADM, | Acquisitions | Public Works and Government Services Canada
- Barbara Glover, ADM | Departmental Oversight | Public Works and Government Services Canada
Subject Matter of the communication: Government Procurement
Communication date: 2014-10-31
Posted date: 2014-11-17
Communication number: 5088-339047 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kelvin Ogilvie, Honourable Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2014-06-18
Posted date: 2014-07-15
Communication number: 5088-330045 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Holder, MINISTER OF STATE, SCIENCE AND TECHNOLOGY | Industry Canada
Subject Matter of the communication: Science and Technology
Communication date: 2014-04-02
Posted date: 2014-07-15
Communication number: 5088-330046 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Blake Richards, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2013-11-18
Posted date: 2013-12-19
Communication number: 5088-311529 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Diane Finley, Minister | Human Resources and Skills Development Canada (HRSDC)
- Adria Minsky, Director of Policy | Human Resources and Skills Development Canada (HRSDC)
- Ann Matejicka, Chief of Staff | Human Resources and Skills Development Canada (HRSDC)
- Frank Vermaeten, Assistant Deputy Minister | Human Resources and Skills Development Canada (HRSDC)
Subject Matter of the communication: Labour
Communication date: 2013-02-07
Posted date: 2013-02-19
Communication number: 5088-260150 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Christian Paradis, Minister | Industry Canada
- Sophie Arvanitis, Director of Policy | Industry Canada
Subject Matter of the communication: Economic Development
Communication date: 2013-02-07
Posted date: 2013-02-19
Communication number: 5088-260132 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Lise Anne Jackson, Policy Analyst- Trade | Foreign Affairs and International Trade Canada (DFAITC)
- Patrick McIntyre, Policy Analyst | Industry Canada
Subject Matter of the communication: Economic Development
Communication date: 2013-02-06
Posted date: 2013-02-19
Communication number: 5088-260131 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Deputy Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Economic Development
Communication date: 2013-02-06
Posted date: 2013-02-19
Communication number: 5088-260130 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Brison, Member of Parliament | House of Commons
- Roger Cuzner, Member of Parliament | House of Commons
- Geoff Regan, Member of Parliament | House of Commons
Subject Matter of the communication: Economic Development
Communication date: 2013-02-06
Posted date: 2013-02-19
Communication number: 5088-260129 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ailish Campbell, Director General | manufacturing and Life Sciences Branch | Industry Canada
Subject Matter of the communication: Economic Development
Communication date: 2013-01-16
Posted date: 2013-02-19
Communication number: 5088-260152 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Ring, Assistant Deputy Minister | Public Procurement | Public Works and Government Services Canada
Subject Matter of the communication: Health
Communication date: 2012-11-29
Posted date: 2012-12-13
Communication number: 5088-250341 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rainier Englehardt, Assistant Deputy Minister | Infectious Diseases | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2012-11-22
Posted date: 2012-12-13
Communication number: 5088-250340 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Greg Taylor, Acting Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2012-11-22
Posted date: 2012-12-13
Communication number: 5088-250339 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Glenda Yeates, Deputy Minister | Health Canada (HC)
- Krista Outhwaite, Associate Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2012-11-22
Posted date: 2012-12-13
Communication number: 5088-250337 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Assistant Deputy Minister | Health products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2012-11-22
Posted date: 2012-12-13
Communication number: 5088-250336 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Karl Belanger, Chief of Staff | Official Leader of the Opposition | House of Commons
Subject Matter of the communication: Health
Communication date: 2012-11-13
Posted date: 2012-12-13
Communication number: 5088-250334 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kristen Hillman, Chief Negotiator | TransPacific Partnership, International Trade Canada | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2012-10-05
Posted date: 2012-11-14
Communication number: 5088-244982 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jen Petersen, Parliamentary Assistant | Office of Helen Laverdiere, MP For Laurier- Sainte Marie | House of Commons
- Miriam Rycroft, Policy Analyst | NDP OLO Parliamentary Affairs | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-10-02
Posted date: 2012-11-14
Communication number: 5088-244983 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- John Knubley, Deputy Minister | Industry Canada
- Simon Kennedy, Associate Deputy Minister | Industry Canada
- Phil Jennings, Assistant Deputy Minister | Industry Canada
Subject Matter of the communication: Industry
Communication date: 2012-09-26
Posted date: 2012-10-12
Communication number: 5088-240686 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
- Rainier Englehardt, Assistant Deputy Minister | Infectious Diseases | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2012-09-26
Posted date: 2012-10-12
Communication number: 5088-240685 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Shuvaloy Majumdar, Senior Policy Advisor | Office of the Minister | Foreign Affairs and International Trade Canada (DFAITC)
- Idee Inyangudor, Senior Policy Advisor | Canadian International Development Agency | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Development
Communication date: 2012-09-21
Posted date: 2012-10-15
Communication number: 5088-241054 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Brian Storseth, Member of Parliament | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-06-21
Posted date: 2012-07-20
Communication number: 5088-231289 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ian Stewart, ADM Strategic Policy | Industry Canada
- Simon Kennedy, Associate DM | Industry Canada
- Phil Jennings, Associate ADM | Industry Canada
Subject Matter of the communication: Science and Technology, Research and Development
Communication date: 2012-06-21
Posted date: 2012-07-20
Communication number: 5088-231272 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ben Lobb, Member of Parliament | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-06-19
Posted date: 2012-07-20
Communication number: 5088-231271 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jonathon Finkelstein, Senior Tax Adviser, Minister of Finance's office | Finance Canada (FIN)
Subject Matter of the communication: Financial Institutions
Communication date: 2012-06-15
Posted date: 2012-07-20
Communication number: 5088-231270 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Armstrong, Member of Parliament | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-06-12
Posted date: 2012-07-20
Communication number: 5088-231269 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Fast, Minister of Foreign Affairs and International Trade | Foreign Affairs and International Trade Canada (DFAITC)
- Lise-Ann Jackson, Senior Advisor, Policy and Stakeholder Relations, office of the Minister | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2012-05-28
Posted date: 2012-06-12
Communication number: 5088-226469 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Drew Campbell, Director of Stakeholder Relations | Prime Minister's Office (PMO)
- David Belous, Advisor, Stakeholder Relations | Prime Minister's Office (PMO)
- Bruce Winchester, Director of Policy, Office of the Minister of Industry | Industry Canada
- Frank Beaudry, Policy Advisor, Office of the Minister of Finance | Finance Canada (FIN)
Subject Matter of the communication: International Trade
Communication date: 2012-05-28
Posted date: 2012-06-12
Communication number: 5088-226465 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Don Stephenson, Chief Negotiator (Comprehensive Economic Partnership Agreement with India) | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2012-05-28
Posted date: 2012-06-12
Communication number: 5088-226464 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rob Stewart, ADM, International Trade and Finance | Finance Canada (FIN)
Subject Matter of the communication: International Trade
Communication date: 2012-05-28
Posted date: 2012-06-12
Communication number: 5088-226462 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rob Merrifield, Member of Parliament, Chair of Standing Committee on International Trade | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2012-05-28
Posted date: 2012-06-12
Communication number: 5088-226460 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Danya Vered, Policy Analyst, Office of the Liberal Leader | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-03-13
Posted date: 2012-04-13
Communication number: 5088-217869 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gary Goodyear, Minister of State, Science and Technology | House of Commons
Subject Matter of the communication: Health
Communication date: 2012-03-06
Posted date: 2012-04-13
Communication number: 5088-217852 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Lisa Raitt, Minister of Labour | Human Resources and Skills Development Canada (HRSDC)
Subject Matter of the communication: International Trade
Communication date: 2012-03-02
Posted date: 2012-04-13
Communication number: 5088-217850 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Verheul, Chief Negotiator CETA | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2012-03-02
Posted date: 2012-04-13
Communication number: 5088-217848 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: International Trade
Communication date: 2012-03-02
Posted date: 2012-03-05
Communication number: 5088-210359 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Lisa Raitt, Member of Parliament | House of Commons
Subject Matter of the communication: Labour
Communication date: 2012-03-02
Posted date: 2012-03-05
Communication number: 5088-210358 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leona Aglukkaq, Minister of Health | Health Canada (HC)
- Scott Tessier, Chief of Staff to Minister | Health Canada (HC)
- Paul Glover, Assistant Deputy Minister | Health Canada (HC)
- Abby Hoffman, Assistant Deputy Minister | Health Canada (HC)
- Amanda Gordon, Executive Assistant to the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-03-01
Posted date: 2012-04-13
Communication number: 5088-217828 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leona Aglukkaq, Minister | Health Canada (HC)
- Scott Tessier, Chief of Staff to Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2012-03-01
Posted date: 2012-03-05
Communication number: 5088-210357 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kelvin Ogilvie, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2012-02-29
Posted date: 2012-03-05
Communication number: 5088-210356 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Ring, Assistant Deputy Minister | Public Works and Government Services Canada
Subject Matter of the communication: Health
Communication date: 2012-02-29
Posted date: 2012-03-05
Communication number: 5088-210329 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Aaron Seal, Director of Policy | Finance Canada (FIN)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-02-28
Posted date: 2012-03-05
Communication number: 5088-210355 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sean O'Leary, Policy Analyst | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-02-28
Posted date: 2012-03-05
Communication number: 5088-210354 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Andre Bachand, Senior Advisor | Prime Minister's Office (PMO)
- Sean Speer, Senior Economic Policy Advisor | Prime Minister's Office (PMO)
- Andrea van Vugt, Policy Advisor | Prime Minister's Office (PMO)
- Phil Harwood, Policy Advisor | Prime Minister's Office (PMO)
- Stefan Stefanov, Intern | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-02-28
Posted date: 2012-03-05
Communication number: 5088-210328 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rick Theis, Policy Analyst, Liberal Leader's Office | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-02-24
Posted date: 2012-03-05
Communication number: 5088-210353 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jordan Leichnitz, Policy Analyst, NDP Leader's Office | House of Commons
Subject Matter of the communication: International Development
Communication date: 2012-02-23
Posted date: 2012-03-05
Communication number: 5088-210352 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Tessier, Chief of Staff to Minister | Health Canada (HC)
Subject Matter of the communication: International Trade
Communication date: 2012-02-21
Posted date: 2012-03-05
Communication number: 5088-210351 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Devinder Shory, Member of Parliament | House of Commons
- Rob Merrifield, Member of Parliament | House of Commons
- Russ Hiebert, Member of Parliament | House of Commons
- Ed Holder, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2012-02-15
Posted date: 2012-02-17
Communication number: 5088-208227 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Drew Capbell, Director of Stakeholder Relations | Prime Minister's Office (PMO)
- Jeannie Smith, Chief of Staff to Minister of State, Science and Technology | Industry Canada
- Ian West, Chief of Staff, Minister | Canada Revenue Agency (CRA)
- Sophia Arvanitis, Senior Analyst | Finance Canada (FIN)
Subject Matter of the communication: Taxation and Finance, Research and Development
Communication date: 2012-02-15
Posted date: 2012-02-17
Communication number: 5088-208207 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bernard Valcourt, Member of Parliament | House of Commons
- Dean Allison, Member of Parliament | House of Commons
- Mark Adler, Member of Parliament | House of Commons
- Jay Aspin, Member of Parliament | House of Commons
- Colin Carrie, Member of Parliament | House of Commons
- Vincent Caron, Policy Advisor & Caucus Liaison | Atlantic Canada Opportunities Agency (ACOA)
Subject Matter of the communication: Taxation and Finance, Research and Development
Communication date: 2012-02-15
Posted date: 2012-02-17
Communication number: 5088-208188 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: International Trade
Communication date: 2012-02-09
Posted date: 2012-03-05
Communication number: 5088-210350 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kirsty Duncan, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2012-02-09
Posted date: 2012-03-05
Communication number: 5088-210349 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tim Sargent, Assistant Secretary to the Cabinet Economic and Regional Development Policy | Privy Council Office (PCO)
Subject Matter of the communication: International Trade
Communication date: 2012-02-09
Posted date: 2012-03-05
Communication number: 5088-210347 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Fast, Member of Parliament, Minister | House of Commons
- Maxime Bernier, Member of Parliament, Minister | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2012-02-03
Posted date: 2012-03-05
Communication number: 5088-210330 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Glenda Yeates, Deputy Minister | Health Canada (HC)
- Paul Glover, Assistant Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2012-01-17
Posted date: 2012-02-15
Communication number: 5088-207384 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Tessier, Chief of Staff to the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2012-01-10
Posted date: 2012-02-15
Communication number: 5088-207383 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Christian Paradis, Minister | Industry Canada
- Sean O'Leary, Policy Advisor | Industry Canada
- Bruce Winchester, Director of Policy | Industry Canada
- Jillian Andrews, Policy Advisor | Industry Canada
Subject Matter of the communication: Industry, International Trade
Communication date: 2011-12-08
Posted date: 2011-12-08
Communication number: 5088-197359 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Fast, Minister of Trade | Foreign Affairs and International Trade Canada (DFAITC)
- Louise Girouard, Director of Trade MINO | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Industry, International Trade
Communication date: 2011-12-08
Posted date: 2011-12-08
Communication number: 5088-197350 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bob Rae, Member of Parliament | House of Commons
- John McCallum, Member of Parliament | House of Commons
- Scott Brison, Member of Parliament | House of Commons
- Ted Tsu, Member of Parliament | House of Commons
- Joyce Murray, Member of Parliament | House of Commons
- Geoff Regan, Member of Parliament | House of Commons
Subject Matter of the communication: Industry, International Trade
Communication date: 2011-12-08
Posted date: 2011-12-08
Communication number: 5088-197349 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steven Farber, Policy Advisor | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Development
Communication date: 2011-12-07
Posted date: 2012-01-18
Communication number: 5088-203848 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Wilks, Member of Parliament | House of Commons
- Mike Wallace, Member of Parliament | House of Commons
- James Rajotte, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-12-07
Posted date: 2011-12-08
Communication number: 5088-197370 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gerald Keddy, Member of Parliament | House of Commons
- Ron Cannan, Member of Parliament | House of Commons
- Ed Holder, Member of Parliament | House of Commons
- Rob Clarke, Member of Parliament | House of Commons
Subject Matter of the communication: Industry, International Trade
Communication date: 2011-11-15
Posted date: 2011-12-08
Communication number: 5088-197369 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Benoit Violette, Senior Policy Advisor | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-11-15
Posted date: 2011-12-08
Communication number: 5088-197366 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Patrick McIntyre, Director of Policy | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-11-15
Posted date: 2011-12-08
Communication number: 5088-197365 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gary Goodyear, Minister of State, Science and Technology | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-11-15
Posted date: 2011-12-08
Communication number: 5088-197364 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rob Merrifield, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-11-14
Posted date: 2011-12-09
Communication number: 5088-197445 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jim Sillyer, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2011-11-14
Posted date: 2011-12-08
Communication number: 5088-197368 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jordan Leichnitz, Policy Advisor, Office of the Leader of the Official Opposition | House of Commons
Subject Matter of the communication: International Development
Communication date: 2011-11-14
Posted date: 2011-12-08
Communication number: 5088-197362 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Lisa Raitt, Minister of Labour | Human Resources and Skills Development Canada (HRSDC)
- Brad Butt, Member of Parliament | House of Commons
Subject Matter of the communication: Research and Development
Communication date: 2011-11-10
Posted date: 2011-12-08
Communication number: 5088-197361 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Helene Laverdiere, Member of Parliament | House of Commons
- Jennifer Peterson, Parliamentary Assistant to Helene Laverdiere | House of Commons
- Rahmat Kassam, Legislative Assistant to Mobina Jaffer | Senate of Canada
- Jordan Leichnitz, Policy Advisor, Office of the Leader of the Official Opposition | House of Commons
Subject Matter of the communication: International Development
Communication date: 2011-11-08
Posted date: 2011-12-08
Communication number: 5088-197360 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mobina Jaffer, Senator | Senate of Canada
- Rahmat Kassam, Legislative Assistant to Mobina Jaffer | Senate of Canada
Subject Matter of the communication: International Development
Communication date: 2011-10-28
Posted date: 2011-11-15
Communication number: 5088-194777 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ron Cannan, Member of Parliament | House of Commons
- Ed Holder, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-10-26
Posted date: 2012-02-17
Communication number: 5088-208147 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Devinder Shory, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-10-24
Posted date: 2012-02-17
Communication number: 5088-208107 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jennifer Peterson, Parliamentary Assistant to Helene Laverdiere | House of Commons
Subject Matter of the communication: International Development
Communication date: 2011-10-21
Posted date: 2011-11-15
Communication number: 5088-194775 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Helene Laverdiere, Member of Parliament | House of Commons
Subject Matter of the communication: International Development
Communication date: 2011-10-19
Posted date: 2011-11-15
Communication number: 5088-194772 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Louis Levesque, Deputy Minister | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193338 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Verheul, Chief Negotiator | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193337 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Associate Deputy Minister | Industry Canada
Subject Matter of the communication: International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193336 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193334 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sena O'Leary, Policy Advisor | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193333 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Philip Jennings, Associate Assistant Deputy Minister | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193332 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Christian Paradis, Minister | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193330 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-10-18
Posted date: 2011-11-11
Communication number: 5088-193329 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Wayne Easter, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-10-07
Posted date: 2011-11-15
Communication number: 5088-194770 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Raymond Cote, Member of Parliament | House of Commons
Subject Matter of the communication: International Trade
Communication date: 2011-10-07
Posted date: 2011-11-15
Communication number: 5088-194768 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Robert Chisholm, Member of Parliament | House of Commons
- Mathieu Ravignat, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-09-29
Posted date: 2011-10-14
Communication number: 5088-189101 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Helen Laverdiere, Member of Parliament | House of Commons
Subject Matter of the communication: International Development
Communication date: 2011-09-28
Posted date: 2011-10-14
Communication number: 5088-189105 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Jones, Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2011-09-09
Posted date: 2011-10-14
Communication number: 5088-189094 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Andrea McGuigan, Policy Advisor, Foreign Affairs, Environment & Energy Security | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Intellectual Property, International Trade
Communication date: 2011-08-16
Posted date: 2011-09-15
Communication number: 5088-185890 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: Industry, International Trade
Communication date: 2011-05-10
Posted date: 2011-06-16
Communication number: 5088-173805 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler Jones, Chief Public Health Officer | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2011-05-10
Posted date: 2011-06-16
Communication number: 5088-173804 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Verheul, Chief Trade Negotiator, Canada-European Union | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2010-11-29
Posted date: 2010-12-15
Communication number: 5088-162417 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Keith Martin, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2010-11-04
Posted date: 2010-12-15
Communication number: 5088-162410 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marc Garneau, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2010-11-03
Posted date: 2010-12-15
Communication number: 5088-162399 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Krista Outhwaite, Associate Deputy Minister | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2010-11-03
Posted date: 2010-12-15
Communication number: 5088-162393 (amended from 5088-162382) View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rainier Englehardt, Assistant Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2010-11-03
Posted date: 2010-12-15
Communication number: 5088-162387 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Megan Leslie, MP Halifax | Members of the House of Commons
Subject Matter of the communication: Health, Industry
Communication date: 2010-09-21
Posted date: 2010-10-16
Communication number: 5088-157032 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Carolyn Bennett, MP St.Paul's | Members of the House of Commons
Subject Matter of the communication: Health, Industry
Communication date: 2010-09-21
Posted date: 2010-10-16
Communication number: 5088-157030 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joy Smith, MP Kildonan-St Paul | Chair Standing Committee on Health | Members of the House of Commons
Subject Matter of the communication: Industry
Communication date: 2010-09-21
Posted date: 2010-10-16
Communication number: 5088-157028 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leah Canning, Director of Policy | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Industry
Communication date: 2010-09-21
Posted date: 2010-10-16
Communication number: 5088-157024 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Canada (HC)
- Tom Ring, Assistant Deputy Minister | Public Works and Government Services Canada
- Rainier Engelhardt, Assistant Deputy Minister | Public Health Agency of Canada (PHAC)
- Mary Chaput, Associate Deputy Minister | Public Health Agency of Canada (PHAC)
- David Butler Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2010-08-26
Posted date: 2010-09-16
Communication number: 5088-154670 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jane Billings, Senior ADM | Planning and Public Health Integration | Public Health Agency of Canada (PHAC)
- Tom Ring, ADM | Acquisitions Branch | Public Works and Government Services Canada
Subject Matter of the communication: Health
Communication date: 2010-07-28
Posted date: 2010-08-17
Communication number: 5088-153636 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dr. David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2010-05-25
Posted date: 2010-06-16
Communication number: 5088-149336 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Peter Van Loan, Minister of International Trade | Foreign Affairs and International Trade Canada | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
Communication date: 2010-03-10
Posted date: 2010-04-12
Communication number: 5088-145445 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | Health Canada | Health Canada (HC)
- Meena Ballantyne, Assistant Deputy Minister | Health Canada | Health Canada (HC)
- Jane Billings, Senior Assistant Deputy Minister | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Industry
Communication date: 2010-03-10
Posted date: 2010-04-12
Communication number: 5088-145444 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mary Chaput, Associate Deputy Minister | OFFICE OF THE ASSOCIATE DEPUTY MINISTER | Public Health Agency of Canada (PHAC)
- Jane Billings, Senior Assistant Deputy Minister | DEPUTY MINISTER'S OFFICE | Public Health Agency of Canada (PHAC)
- Leah Canning, Director of Policy | MINISTER'S OFFICE | Health Canada (HC)
- Meena Ballantyne, Assistant Deputy Minister | Health Canada | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2010-01-25
Posted date: 2010-02-11
Communication number: 5088-136854 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | DEPUTY MINISTER'S OFFICE | Health Canada (HC)
- Mary Chaput, Associate Deputy Minister | Office of the Associate Deputy Ministr | Public Health Agency of Canada (PHAC)
- Dr. David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2010-01-14
Posted date: 2010-02-11
Communication number: 5088-136835 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dr. David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-12-21
Posted date: 2010-01-12
Communication number: 5088-134774 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tim Vail, Director of Communications | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-11-24
Posted date: 2009-12-10
Communication number: 5088-132020 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
- Mary Chaput, Associate Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-11-23
Posted date: 2009-12-10
Communication number: 5088-132019 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sabrina Anzini, Special Advisor, Legal Affairs and Policy | Prime Minister's Office (PMO)
- Isabelle Bouchard, Issues Management | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2009-11-06
Posted date: 2009-12-10
Communication number: 5088-132018 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel Jean, Deputy Secretary to the Cabinet | Privy Council Office (PCO)
Subject Matter of the communication: Health
Communication date: 2009-11-05
Posted date: 2009-12-10
Communication number: 5088-132017 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-11-04
Posted date: 2009-12-10
Communication number: 5088-132016 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sabrina Anzini, Special Advisor, Legal Affairs and Policy | Prime Minister's Office (PMO)
- Isabelle Bouchard, Issues Management | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2009-11-02
Posted date: 2009-12-10
Communication number: 5088-132014 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Tessier, Chief of Staff | Office of the Minister | Health Canada (HC)
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-10-30
Posted date: 2009-11-16
Communication number: 5088-127440 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sabrina Anzini, Special Advisor, Legal Affairs and Policy | Prime Minister's Office (PMO)
- Isabelle Bouchard, Issue Management | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2009-10-29
Posted date: 2009-11-16
Communication number: 5088-127439 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sabrina Anzini, Special Advisor, Legal Affairs and Policy | Prime Minister's Office (PMO)
- Isabelle Bouchard, Issue Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2009-10-21
Posted date: 2009-11-16
Communication number: 5088-127438 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-10-21
Posted date: 2009-11-16
Communication number: 5088-127437 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-10-07
Posted date: 2009-11-16
Communication number: 5088-127436 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-10-06
Posted date: 2009-11-16
Communication number: 5088-127435 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-10-02
Posted date: 2009-11-16
Communication number: 5088-127434 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Wilson, Director, Policy | Prime Minister's Office (PMO)
- Sabrina Anzini, Special Advisor, Legal Affairs and Policy | Prime Minister's Office (PMO)
- Isabelle Bouchard, Issues Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health
Communication date: 2009-09-11
Posted date: 2009-10-15
Communication number: 5088-124175 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
- Scott Tessier, Chief of Staff | Office of the Minister | Health Canada (HC)
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-09-11
Posted date: 2009-10-15
Communication number: 5088-124156 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tim Vail, Director of Communication | Office of the Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-09-03
Posted date: 2009-10-15
Communication number: 5088-124155 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-09-02
Posted date: 2009-10-15
Communication number: 5088-124137 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jane Billings, Senior Assistant Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-07-23
Posted date: 2009-08-14
Communication number: 5088-116694 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-07-21
Posted date: 2009-08-14
Communication number: 5088-116616 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-07-14
Posted date: 2009-08-14
Communication number: 5088-116614 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-06-29
Posted date: 2009-07-16
Communication number: 5088-111916 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-05-21
Posted date: 2009-06-15
Communication number: 5088-107754 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister | Industry Canada
- Elie Salibi, Policy Advisor | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Relations, Science and Technology, Taxation and Finance
Communication date: 2009-05-19
Posted date: 2009-06-15
Communication number: 5088-107795 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister | Industry Canada
- Elie Salibi, Policy Advisor | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology, Taxation and Finance
Communication date: 2009-05-18
Posted date: 2009-06-15
Communication number: 5088-107794 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dani Shaw, Chief of Staff | Health Canada (HC)
- Leah Canning, Policy Advisor | Health Canada (HC)
- Leona Aglukkaq, Minister | Health Canada (HC)
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2009-05-12
Posted date: 2009-06-15
Communication number: 5088-107755 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-05-05
Posted date: 2009-06-15
Communication number: 5088-103355 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2009-04-22
Posted date: 2009-05-13
Communication number: 5088-103354 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2009-03-27
Posted date: 2009-04-14
Communication number: 5088-100467 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2009-03-25
Posted date: 2009-04-14
Communication number: 5088-100466 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leah Canning, Policy Advisor | Office of the Minister | Health Canada (HC)
- William King, Chief of Staff | Office of the Minister | Industry Canada
- Benoit Violette, Senior Policy Advisor | Office of the Minister | Industry Canada
Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property, International Trade, Science and Technology, Taxation and Finance
Communication date: 2009-01-22
Posted date: 2009-02-11
Communication number: 5088-92894 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
- Meena Ballantyne, Assistant Deputy Minister | Health Products & Food Branch | Health Canada (HC)
- Dr. David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
- Dr. Danielle Grondin, A/ Assistant Deputy Minister | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2009-01-21
Posted date: 2009-02-11
Communication number: 5088-92896 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2009-01-21
Posted date: 2009-02-11
Communication number: 5088-92895 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2008-12-23
Posted date: 2009-01-15
Communication number: 5088-89135 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2008-12-22
Posted date: 2009-01-15
Communication number: 5088-84035 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Brien Benoit, Chairperson | Patented Medicine Prices Review Board (PMPRB)
Subject Matter of the communication: Consumer Issues, Health, Industry, Science and Technology
Communication date: 2008-10-21
Posted date: 2008-11-14
Communication number: 5088-84034 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2008-10-20
Posted date: 2008-11-14
Communication number: 5088-83414 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-08-17
Posted date: 2008-09-15
Communication number: 5088-80114 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Laurie Throness, Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-08-13
Posted date: 2008-09-15
Communication number: 5088-77894 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Butler-Jones, Chief Public Health Officer | Office of the Chief Public Health Officer | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2008-07-23
Posted date: 2008-08-14
Communication number: 5088-77485 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister of Health | Deputy Minister's Office | Health Canada (HC)
- Suzanne Vinet, Associate Deputy Minister | Associate Deputy Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-07-23
Posted date: 2008-08-14
Communication number: 5088-74714 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister of Health | Minister's Office | Health Canada (HC)
- Laurie Throness, Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-07-23
Posted date: 2008-08-14
Communication number: 5088-74695 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Robert Serpe, Policy Advisor | Minister's Office | Finance Canada (FIN)
- James Flaherty, Minister of Health | Minister's Office | Finance Canada (FIN)
Subject Matter of the communication: Health
Communication date: 2008-07-23
Posted date: 2008-08-14
Communication number: 5088-74674 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Robert Serpe, Policy Advisor | Minister's Office | Finance Canada (FIN)
Subject Matter of the communication: Health
Communication date: 2008-07-22
Posted date: 2008-08-14
Communication number: 5088-74694 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leah Canning, Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-07-09
Posted date: 2008-08-14
Communication number: 5088-74734 View associated registration

Sridhar Venkatesh, General Manager and President (Corporation)

Learn more...

Results below are sorted by posted date, beginning with the most recent.

Results 1-289 of 289

GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
- Erin Henry, Director General | Centre for Immunization Programs and Surveillance | Public Health Agency of Canada (PHAC)
- Jacqueline Kosche , Director | Vaccine Logistics and Operations | Public Health Agency of Canada (PHAC)
- Christina Jensen, Manager, Canadian Immunization Guide | National Advisory Committee on Immunization Secretariat | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-08-19
Posted date: 2024-09-16
Communication number: 5088-613501 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Eshan Naik, Director of Policy | Minister's office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-08-14
Posted date: 2024-09-16
Communication number: 5088-612849 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Fatima Asghar, Policy Advisor | Health Canada (HC)
- Ella Alvarado De Catleugh , Intern | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-07-22
Posted date: 2024-08-15
Communication number: 5088-611604 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ophelia John, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2024-07-11
Posted date: 2024-08-15
Communication number: 5088-610284 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Judith Seidman, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2024-06-26
Posted date: 2024-07-15
Communication number: 5088-609321 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Cid Cabillan, Policy Advisor | Immigration, Refugees and Citizenship Canada (IRCC)
Subject Matter of the communication: Health
Communication date: 2024-06-25
Posted date: 2024-07-15
Communication number: 5088-609276 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mohamed-Iqbal Ravalia, Senator | Senate of Canada
Subject Matter of the communication: Health
Communication date: 2024-06-19
Posted date: 2024-07-15
Communication number: 5088-609065 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Kmiec, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2024-06-13
Posted date: 2024-07-15
Communication number: 5088-607371 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn, Director | Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
- Caroline Menard, Manager | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development, Health
Communication date: 2024-06-04
Posted date: 2024-07-15
Communication number: 5088-606104 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joanna Lam, Policy Advisor | Minister's Office | Indigenous Services Canada (ISC)
Subject Matter of the communication: Health
Communication date: 2024-05-30
Posted date: 2024-06-15
Communication number: 5088-605533 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Erin Henry, Director General | Public Health Agency of Canada (PHAC)
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
- Heather Deehan, Executive Director, Vaccine Distribution and Logistics | Public Health Agency of Canada (PHAC)
- Kelsey Young, Deputy Executive Secretary | NACI | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-05-17
Posted date: 2024-06-15
Communication number: 5088-605174 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rodrigo Arancibia, Director | Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development, Health
Communication date: 2024-04-30
Posted date: 2024-05-15
Communication number: 5088-601821 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Semhar Zerat, Director | Programs and Partnerships Division | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-601822 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jaxson Khan, Sr Policy Advisor | MINISTER OF INNOVATION, SCIENCE AND INDUSTRY | Innovation, Science and Economic Development Canada (ISED)
- Laurel Chester, Senior Advisor | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Government Procurement
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-600955 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Colin Deacon, Senator | Senate of Canada
Subject Matter of the communication: Economic Development
Communication date: 2024-04-16
Posted date: 2024-05-15
Communication number: 5088-600954 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Francis Bilodeau, Associate Deputy Minister | Office of the Associate Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Andrea Johnston, Assistant deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Etienne-Rene Massie, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2024-04-15
Posted date: 2024-05-15
Communication number: 5088-600953 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mark Schaan, Senior Assistant Deputy Minister | Strategy and Innovation Policy Sector - Assistant Deputy Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Economic Development, Research and Development
Communication date: 2024-04-15
Posted date: 2024-05-15
Communication number: 5088-600952 View associated registration
GlaxoSmithKline Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joel Denis, Director General | Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2024-04-04
Posted date: 2024-05-15
Communication number: 5088-599236 View associated registration

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
A/Director, GeoConnections Secretariat Natural Resources Canada, Earth Sciences Sector	June 2005 to March 2007	Not a designated office

Date Modified:: 2024-04-04

Search and menus

Language selection

Registration - In-house Corporation

GlaxoSmithKline Inc. / Sridhar Venkatesh, General Manager and President

Registration Information

Associated Communications

Version 20 of 68 (2011-10-18 to 2011-12-08)

Version 20 of 68 (2011-10-18 to 2011-12-08)

Subject Matters

Subject matters added through a monthly communication report

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Government institutions added through a monthly communication report

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties